Clinical trials: Gastrooesophageal Cancer
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Gastrointestinal Neoplasm, Gastric Adenocarcinoma
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
The investigators hypothesize IXO chemotherapy will have an improvement in response rate and acceptable toxicity for uncurable metastatic gastric cancer compared to historical controls.
- Trial name
- IXOGoo1 (NCT01129310)
- Testing
- Irinotecan-Capecitabine-Oxaliplatin
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- AHS Cancer Control Alberta
Gastro-Intestinal Cancer
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of…
- Trial name
- NCT05332002
- Testing
- Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Rutgers, The State University of New Jersey
Gastric Cancer, Gastroesophageal Cancer (GC)
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally…
- Trial name
- NCT05632939
- Testing
- ASKB589 +CAPOX+Sintilimab/Tislelizumab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- AskGene Pharma, Inc.
Colorectal Cancer, Gastroesophageal Cancer
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Background: People with colorectal cancer (CRC) or gastroesophageal cancer (GEC) must often have major surgery to remove tumors from the esophagus, stomach, colon, or rectum.
- Trial name
- NCT06410534
- Testing
- nivolumab, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
This study will characterize the safety and tolerability and identify the recommended Phase 2 dose (RP2D) of subcutaneous (SC) ALKS 4230 as monotherapy and in combination with pembrolizumab.
- Trial name
- NCT03861793
- Testing
- ALKS 4230, Pembrolizumab
- Where
- 48 sites in United States, Canada and 4 more
- Volunteers
- 116 people
- Sponsor
- Mural Oncology, Inc
Cancer of Esophagus, Esophagogastric Junction Disorder
CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1
This is an exploratory observational biomarker study in approximately 100 eligible patients with resectable adenocarcinomas of the esophagus and gastro- esophageal junction (GEJ) type I-II (GEAC) to investigate the difference…
- Trial name
- CIRCULATE1 (NCT04455282)
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Solid Tumors
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
IMAB362 is a monoclonal antibody specific for gastric or lower esophageal adenocarcinoma. Preclinically IMAB362 was shown to inhibit tumor growth and to kill cancer cells by indirect (complement-dependent cytotoxicity…
- Trial name
- NCT01197885
- Testing
- IMAB362
- Where
- 21 sites in Bulgaria, Germany and 3 more
- Volunteers
- 54 people
- Sponsor
- Ganymed Pharmaceuticals GmbH
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Gastric Adenocarcinoma, GastroEsophageal Cancer
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with pembrolizumab in subjects with advanced gastric and gastroesophageal adenocarcinoma.
- Trial name
- NCT04164979
- Testing
- Cabozantinib, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, Irvine
Cancer of Stomach, Gastroesophageal Cancer
Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to evaluate the safety and efficacy of pegamotecan (PEG-camptothecin) in patients with pathologically-diagnosed locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal…
- Trial name
- NCT00080002
- Testing
- Pegamotecan
- Sponsor
- Enzon Pharmaceuticals, Inc.
Gastrostomy, Gastric
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
- Conditions
- Gastrostomy, Gastric, GastroEsophageal Cancer
- Trial name
- NCT05205343
- Testing
- Standard of Care, Control Group
- Where
- 4 sites in United States, Japan and 1 more
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Gastroesophageal Cancer
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
The goal of this clinical research study is to learn if a combination of the investigational drug oxaliplatin with 5-Fluorouracil (5-FU) (given at the same time as radiation therapy) is as effective as a combination of these two…
- Trial name
- NCT00525915
- Testing
- 5-Fluorouracil, Oxaliplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma, GastroEsophageal Cancer
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma.
- Trial name
- NCT04074343
- Testing
- TAS-102, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Gastroesophageal Junction Adenocarcinoma
Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction
Stage I：preoperative therapy Capecitabine plus oxaliplatin with concurrent radiotherapy is superior to surgery alone ; Stage II: Perioperative therapy Perioperative Capecitabine plus oxaliplatin with Concurrent radiotherapy is…
- Trial name
- A-C (NCT01962246)
- Testing
- Oxaliplatin; Capecitabine, Oxaliplatin; Capecitabine; concurrent radiotherapy
- Where
- China
- Volunteers
- 169 people
- Sponsor
- Hebei Medical University
Gastric or Gastroesophageal Cancer
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
The main objectives of this study are: To determine the recommended dose (RD) of FPA144 in participants with gastric or gastroesophageal cancer (hereafter referred to as gastric cancer) To evaluate the safety of escalating doses…
- Trial name
- NCT05913115
- Testing
- FPA144
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Amgen
Gastroesophageal Cancer, Adenocarcinoma
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
This study will test the combination of abemaciclib with pembrolizumab in patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma that is metastatic or cannot be surgically removed, and who have progressed…
- Trial name
- NCT03997448
- Testing
- Pembrolizumab, Abemaciclib
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Nataliya Uboha
Gastric Cancer, GastroEsophageal Cancer
Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America
Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region.
- Conditions
- Gastric Cancer, GastroEsophageal Cancer, Pancreatic Cancer
- Trial name
- GASPAR (NCT05924789)
- Testing
- Observational study
- Where
- 6 sites in Argentina, Brazil
- Volunteers
- 120 people
- Sponsor
- Latin American Cooperative Oncology Group
Gastric Cancer, Esophageal Adenocarcinoma
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies.
- Conditions
- Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- CAMILLA (NCT03539822)
- Testing
- Cabozantinib, Durvalumab, Tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 117 people
- Sponsor
- Anwaar Saeed
Gastrointestinal Cancer
Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
The goal of this clinical research study is to learn if hyperthermic intraperitoneal chemotherapy (HIPEC) will help to control the disease in patients with Stage 4 stomach or gastroesophageal cancer.
- Trial name
- NCT02092298
- Testing
- Mitomycin C, Cisplatin, Sodium Thiosulfate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center